A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder

Acta Psychiatrica Scandinavica

Volumn 140, Issue 2, 2019, Pages 94-115

  Hui, T P ^a   Kandola, A ^a   Shen, L ^a   Lewis, G ^a   Osborn, D P J ^a   Geddes, J R ^b   Hayes, J F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

bipolar disorder; clinical aspects; lithium

Indexed keywords

LITHIUM; LITHIUM DERIVATIVE; TRANQUILIZER;

ALCOHOL CONSUMPTION; BIPOLAR DISORDER; BODY MASS; DRUG USE; FAMILY HISTORY; HOSPITALIZATION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL SUPPORT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; FEMALE; MALE; PREDICTIVE VALUE; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIMANIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; FEMALE; HOSPITALIZATION; HUMANS; LITHIUM; LITHIUM COMPOUNDS; MALE; OBSERVATIONAL STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85069049930     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.13062     Document Type: Review

References (94)

1. Health NCCfM. Bipolar disorder: The NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. Leicester, UK: British Psychological Society 2018.
2. Goodwin G, Haddad P, Ferrier I et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30:495–553.
3. Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97–170.
4. Garnham J, Munro A, Slaney C et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007;104:185–190.
5. Fornaro M, De Berardis D, Anastasia A et al. The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: a plea for further research attention. Psychiatry Res 2018;269:658–672.
6. Hou L, Heilbronner U, Degenhardt F et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 2016;387:1085–1093.
7. Scott J, Etain B, Bellivier F. Can an integrated science approach to precision medicine research improve lithium treatment in bipolar disorders? Front Psychiatry 2018;9:360.
8. Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005;7:404–417.
9. Tighe SK, Mahon PB, Potash JB. Predictors of lithium response in bipolar disorder. Therapeutic Adv Chronic Dis 2011;2:209–226.
10. Bozkurt HT, Erbasan V, Eğilmez Ü, Şen B, Aydın M, Altınbaş K. Clinical, biological and genetic predictors of lithium treatment response. Curr Approach Psychiatry/Psikiyatride Guncel Yaklasimlar. 2018;10:395-416.
11. Rybakowski JK. Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci. 2014;5:413–421.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–269.
13. Koukopoulos A, Reginaldi D, Tondo L, Visioli C, Baldessarini R. Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias. J Affect Disord 2013;151:105–110.
14. Bratti IM, Baldessarini RJ, Baethge C, Tondo L. Pretreatment episode count and response to lithium treatment in manic-depressive illness. Harvard Rev Psychiatry 2003;11:245–256.
15. Faedda GL, Baldessarini RJ. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991;148:1237.
16. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283:2008–2012.
17. Maj M, Del Vecchio M, Starace F, Pirozzi R, Kemali D. Prediction of affective psychoses response to lithium prophylaxis: the role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatr Scand 1984;69:37–44.
18. Coppen A, Peet M, Bailey J et al. Double-blind and open prospective studies of lithium prophylaxis in affective disorders. Psychiatr, Neurol, Neurochir 1973;76:501–510.
19. Grof P, Duffy A, Cavazzoni P et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002;63:942–947.
20. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377–384.
21. Boland A, Cherry G, Dickson R. Doing a systematic review: A student's guide. London, UK: Sage, 2017.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
23. Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: results from a nationwide register-based study. Int Clin Psychopharmacol 2011;26:323–328.
24. Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 2014;205:214–220.
25. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229–233.
26. Gasperini M, Scherillo P, Manfredonia MG, Franchini L, Smeraldi E. A study of relapses in subjects with mood disorder on lithium treatment. Eur Neuropsychopharmacol 1993;3:103–110.
27. Serretti A, Lattuada E, Franchini L, Smeraldi E. Melancholic features and response to lithium prophylaxis in mood disorders. Depression Anxiety 2000;11:73–79.
28. Backlund L, Ehnvall A, Hetta J, Isacsson G, Ågren H. Identifying predictors for good lithium response–a retrospective analysis of 100 patients with bipolar disorder using a life-charting method. Eur Psychiatry 2009;24:171–177.
29. Silva LFdAL, Loureiro JC, Franco SCR et al. Assessing treatment response to prophylactic lithium use in patients with bipolar disorder. J Brasileiro de Psiquiatria. 2016;65:9–16.
30. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993;27:138–145.
31. Schürhoff F, Bellivier F, Jouvent R et al. Early and late onset bipolar disorders: two different forms of manic-depressive illness? J Affect Disord 2000;58:215–221.
32. Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D, Endicott J. Family history and symptom levels during treatment for bipolar I affective disorder. Biol Psychiatry 2000;47:1034–1042.
33. Yazıcı O, Kora K, Üçok A, Tunalı D, Turan N. Predictors of lithium prophylaxis in bipolar patients. J Affect Disord 1999;55:133–142.
34. Masui T, Hashimoto R, Kusumi I et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:204–208.
35. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001;178(S41):s184–s190.
36. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123–129.
37. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30–35.
38. Tondo L, Baldessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 1998;155:638–645.
39. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet Part B: Neuropsychiat Genet 2007;144:820–823.
40. Abou-Saleh M. Platelet MAO, personality and response to lithium prophylaxis. J Affect Disord 1983;5:55–65.
41. O'Connell RA, Mayo JA, Eng LK, Jones JS, Gabel RH. Social support and long-term lithium outcome. Br J Psychiatry 1985;147:272–275.
42. Mander A. Clinical prediction of outcome and lithium response in bipolar affective disorder. J Affect Disord 1986;11:35–41.
43. Wei Shan G, Makmor-Bakry M, Salihah Omar M. Long term use of lithium and factors associated with treatment response among patients with bipolar disorder. Psychiatria Danubina 2016;28:146–153.
44. Kusalic M, Engelsmann F. Predictors of lithium treatment responsiveness in bipolar patients. Neuropsychobiology 1998;37:146–149.
45. Kulhara P, Basu D, Mattoo SK, Sharan P, Chopra R. Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J Affect Disord 1999;54:87–96.
46. Sportiche S, Geoffroy PA, Brichant-Petitjean C et al. Clinical factors associated with lithium response in bipolar disorders. Aust N Z J Psychiatry 2017;51:524–530.
47. Calkin CV, Ruzickova M, Uher R et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry 2015;206:52–57.
48. Calkin C, Van De Velde C, Růžičková M et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord 2009;11:650–656.
49. Degenhardt EK, Gatz JL, Jacob J, Tohen M. Predictors of relapse or recurrence in bipolar I disorder. J Affect Disord 2012;136:733–739.
50. Etain B, Lajnef M, Brichant-Petitjean C et al. Childhood trauma and mixed episodes are associated with poor response to lithium in bipolar disorders. Acta Psychiatr Scand 2017;135:319–327.
51. Cakir S, Tasdelen Durak R, Ozyildirim I, Ince E, Sar V. Childhood trauma and treatment outcome in bipolar disorder. J Trauma Dissociat 2016;17:397–409.
52. Sterne JA, Sutton AJ, Ioannidis JP et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
53. Scott J, Geoffroy PA, Sportiche S et al. Cross-validation of clinical characteristics and treatment patterns associated with phenotypes for lithium response defined by the Alda scale. J Affect Disord 2017;208:62–67.
54. Baethge C, Tondo L, Bratti IM et al. Prophylaxis latency and outcome in bipolar disorders. Canadian J Psychiatry 2003;48:449–457.
55. Aronoff MS, Epstein RS. Factors associated with poor response to lithium carbonate: a clinical study. Am J Psychiatry 1970;127:472–480.
56. Mendlewicz J, FieveRR, StalloneF. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry 1973;130:1011–1013.
57. Prien RF, Caffey EM, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1974;31:189–192.
58. Dunner DL, Fleiss JL, Fieve RR. Lithium carbonate prophylaxis failure. Br J Psychiatry 1976;129:40–44.
59. Ananth J, Engelsmann F, Kiriakos R, Kolivakis T. Prediction of lithium response. Acta Psychiatr Scand 1979;60:279–286.
60. Rosenthal NE, Rosenthal LN, Stallone F, Fleiss J, Dunner DL, Fieve RR. Psychosis as a predictor of response to lithium maintenance treatment in bipolar affective disorder. J Affect Disord 1979;1:237–245.
61. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatments. Pharmacopsychiatry 1980;13:156–167.
62. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Progress Neuro-psychopharmacol 1981;5:507.
63. Yang Y. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand 1985;71:171–175.
64. Abou-Saleh M, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986;10:115–125.
65. Bouman TK, Niemantsverdriet-van Kampen JG, Ormel J, Slooff CJ. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders. J Affect Disord 1986;11:275–280.
66. Goodnick PJ, Fieve RR, Schlegel A, Baxter N. Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate. Am J Psychiatry 1987;144:367–369.
67. Grof E, Haag M, Grof P, Haag H. Lithium response and the sequence of episode polarities: Preliminary report on a Hamilton sample. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:199–203.
68. Haag H, Heidorn A, Haag M, Greil W. Sequence of affective polarity and lithium response: preliminary report on Munich sample. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:205–208.
69. Lusznat R, Murphy D, Nunn C. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198–204.
70. Faedda GL, FlorisG, Tondo L, Kukopulos A. Seasonal affective disorder: a retrospective study. Eighth World Congress of Psychiatry Abstracts. Amsterdam, The Netherlands: Elsevier, 1989.
71. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord. 1989;17:237–241.
72. Miller F, Tanenbaum JH, Griffin A, Ritvo E. Prediction of treatment response in bipolar, manic disorder. J Affect Disord. 1991;21:75–77.
73. Grof P, Alda M, Gror E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord. 1994;32:85–95.
74. Maj M, Pirozzi R, Magliano L. Late non-response to lithium prophylaxis in bipolar patients: prevalence and predictors. J Affect Disord 1996;39:39–42.
75. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470–478.
76. Engström C, Åström M, Nordqvist-Karlsson B, Adolfsson R, Nylander P-O. Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol Psychiatry 1997;42:425–433.
77. Greil W, Nikolaus D-SK, Natalia D-PE, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18:455–460.
78. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999;249:227–230.
79. Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord 2000;61:13–22.
80. Swann A, Bowden C, Calabrese J, Dilsaver S, Morris D. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand 2000;101:444–451.
81. Viguera AC, Baldessarini RJ, Tondo L. Response to lithium maintenance treatment in bipolar disorders: comparison of women and men. Bipolar Disord 2001;3:245–252.
82. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002;26:530–536.
83. Hartong E, Moleman P, Hoogduin C, Broekman TG, Nolen WA. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64:144–151.
84. Passmore MJ, Garnham J, Duffy A et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110–114.
85. Washizuka S, Ikeda A, Kato N, Kato T. Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol 2003;6:421–424.
86. Bremer T, Diamond C, McKinney R et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diagnosis Therapy 2007;11:161–170.
87. Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile? Canadian J Psychiatry 2007;52:369–376.
88. Berghofer A, Alda M, Adli M et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry 2008;69:1860.
89. Pfennig A, Schlattmann P, Alda M et al. Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders. Bipolar Disord 2010;12:390–396.
90. Guloksuz S, Altinbas K, Cetin EA et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord 2012;143:148–152.
91. Martinsson L, Wei Y, Xu D et al. Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl Psychiatry 2013;3:e261.
92. Rybakowski JK, Dembinska D, Kliwicki S, Akiskal KK, Akiskal HH. TEMPS-A and long-term lithium response: positive correlation with hyperthymic temperament. J Affect Disord 2013;145:187–189.
93. Tharoor H, Kotambail A, Jain S, Sharma PSVN, Satyamoorthy K. Study of the association of serotonin transporter triallelic 5-HTTLPR and STin2 VNTR polymorphisms with lithium prophylaxis response in bipolar disorder. Psychiatr Genet 2013;23:77–81.
94. Saito S, Fujii K, Ozeki Y et al. Cognitive function, treatment response to lithium, and social functioning in Japanese patients with bipolar disorder. Bipolar Disord 2017;19:552–562.